SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action

Diabetes Care 2020;43:508–511 | https://doi.org/10.2337/dci19-0074

There is compelling evidence that sodium–glucose cotransporter 2 (SGLT2) inhibitors exert cardioprotective and renoprotective effects that are far greater than expected based on their effects on glycemia or glycosuria. In large-scale randomized controlled trials, SGLT2 inhibitors reduce the risk of hospitalizations for heart failure by ~30% and often decrease the risk of cardiovascular death (1). This benefit is particularly striking in patients who have the most marked impairment of systolic function prior to treatment. In parallel, SGLT2 inhibitors also reduce the risk of end-stage renal death and the need for dialysis or renal transplantation by ~30% (2). This benefit is seen even when glomerular filtration rates are sufficiently low to abolish the glycosuric effect of these drugs.

These cardiorenal benefits cannot be explained by an action of SGLT2 inhibitors to lower blood glucose, since similar effects are not seen with antidiabetes drugs that have greater antihyperglycemic actions. Additionally, they cannot be ascribed to a natriuretic action, since these drugs exert only a modest effect on plasma volume or on circulating natriuretic peptides (3).

In 2016, two articles published in Diabetes Care proposed the “thrifty fuel hypothesis” to explain the cardiorenal benefits of SGLT2 inhibitors. Ferrannini et al. (4) and Mudaliar et al. (5) postulated that the action of SGLT2 inhibitors to promote ketogenesis might account for their favorable effects on the heart and kidney because enhanced ketone bodies formation might possibly provide an efficient fuel that could boost the energy state of organs under stress. However, type 2 diabetes represents a state of nutrient overabundance and not energy deprivation, as is evidenced by the enhancement of molecular pathways that promote both energy retention (e.g., through SGLT2 upregulation) and energy storage (6,7). In fact, the stressed heart already preferentially utilizes ketone bodies, and the diabetic kidney is a ketogenic organ (8,9). Therefore, it is not clear that SGLT2 inhibitors can augment ketone body utilization in a manner that improves ATP generation (10). More concerning, ketonemia leads to glomerular hyperfiltration (11), and ketogenesis has been proposed as a contributor to the development of diabetic nephropathy and renal fibrosis (12).

In light of these inconsistencies, it is noteworthy that, in this issue of Diabetes Care, Avogaro et al. (13) propose precisely the opposite hypothesis. Instead of postulating a drug-induced enhancement of fuel supply, the authors suggest that SGLT2 inhibitors induce a “dormancy state” that mimics starvation, i.e., these drugs recapitulate the conditions seen in hibernating animals. How is it possible that our conceptual framework of SGLT2 inhibitors has been turned upside down in only a few years? To comprehend the basis for this paradigm shift, it is important to understand the molecular mechanisms by which the cellular response to nutrient availability determines the health of vital organs.

Activation of SIRT1 and AMPK Signaling as an Adaptive Response to Starvation and Cellular Stress

When cells are stressed by starvation, they activate a transcriptional program that facilitates adaptation to low-nutrient conditions. The enzymes that play a critical role as low-energy sensors include sirtuin 1 (SIRT1) and adenosine monophosphate–activated protein kinase (AMPK). SIRT1 responds to levels of nicotinamide adenine dinucleotide and serves as a redox
Since type 2 diabetes is perceived by cells as a state of nutrient excess, it is accompanied by suppression of SIRT1 and AMPK as well as of autophagy (20–22). In striking contrast, autophagic flux is increased in type 1 diabetes, potentially because it is the hyperinsulinemia of type 2 diabetes—rather than the hyperglycemia—that causes downregulation of autophagy under conditions of glucose intolerance (20). In fact, insulin itself suppresses autophagic flux, potentially by activating Akt/mTOR signaling (23).

Impairment of SIRT1/AMPK signaling and autophagic flux has been implicated in the pathogenesis of cardiac and renal disease in type 2 diabetes. Specifically, a deficiency of SIRT1/AMPK activation and impaired autophagy appears to promote the development of cardiomyocyte dysfunction as well as inflammatory processes in diabetic hearts (20,24). In parallel, suppression of SIRT1/AMPK signaling and autophagy has been evoked to explain the pathogenesis of the glomerular and tubular lesions in diabetic nephropathy, particularly the podocyte injury that can lead to proteinuria and the derangements of proximal and distal tubular function that have been linked to advanced glycation end products (21,22,25).

Intriguingly, the sodium–glucose transporter (SGLT2) is activated by environmental glucose, and thus it acts as a sensor of energy overabundance. Cellular homeostasis favors a counterbalance between SGLT2 and the activation of enzymes that are sensitive to nutrient deprivation. Accordingly, there exists an inverse relationship between the activity of SGLT2 and the intensity of proautophagic signaling in the kidney. High levels of renal tubular glucose promote the expression of SGLT2 but reduce the activation of SIRT1 (26). This intriguing inverse relationship supports the possibility that pharmacological modulation of SGLT2 may represent an effective entry point for regulating the activity of energy/redox sensing molecules that can stimulate autophagic flux and mute cellular stress.

**SGLT2 Inhibitors Produce Cardioprotective and Renoprotective Benefits by Inducing a State of Fasting Mimicry**

It is therefore noteworthy that SGLT2 inhibitors induce a transcriptional paradigm that closely mimics the cellular response to starvation (Fig. 1) (27). These drugs activate SIRT1/AMPK and suppress Akt/mTOR signaling and, consequently, they can promote autophagy, independent of their effects on glucose or insulin (28–31). Importantly, the effect of SGLT2 to stimulate the activity of low-energy sensors is not mediated by interference with SGLT2 protein on an individual cellular level, since it is seen in organs that do not express SGLT2 (30,32).

---

**Figure 1**—Induction of fasting transcriptional paradigm by SGLT2 inhibitors underlies their action to reduce heart failure and serious adverse renal events.
The actions of SGLT2 inhibitors to activate SIRT1/AMPK and suppress Akt/mTOR signaling lead to a reduction in oxidative stress, normalized mitochondrial structure and function, suppression of inflammation, minimization of coronary microvascular injury, enhanced contractile performance, and attenuation of the development of cardiomyopathy (33). The enhanced interplay of AMPK and SIRT1 also underlies the effect of SGLT2 inhibitors to ameliorate glomerular and tubular injury and inflammation and to mitigate the development of nephropathy (34). An increase in AMPK and SIRT1 may also directly enhance tubuloglomerular feedback, thereby linking changes in the activity of these energy sensors to the action of SGLT2 inhibitors to ameliorate glomerular hyperfiltration (35,36). Finally, activation of AMPK/SIRT1 and autophagic flux has been linked to downregulation of ion exchangers that have been implicated in the pathogenesis of diabetic cardiac and renal disease (37,38).

Clinical Evidence Supporting the Proposed Conceptual Framework

Three lines of clinical evidence support the hypothesis that SGLT2 inhibitors exert their effects by the activation of low-energy sensors, which are responsible for mimicking a fasting transcriptional paradigm.

First, SGLT2 inhibitors induce a loss of calories in the urine, and glycosuria is accompanied by a decrease of glucagon synthesis (often with the promotion of glycolysis), increased fatty acid oxidation, and the shrinkage of adipose tissue depots, including the alleviation of organ steatosis (27). Viewed from this perspective, the ketonemia seen with these drugs is not the source of an efficient fuel but instead is a biomarker of a fasting-like transcriptional state.

Second, SGLT2 inhibitors may not only deceive cells into believing that they are fasting but also that they are hypoxic. Oxygen deprivation (like nutrient deprivation) stimulates AMPK and SIRT1 (39,40). The latter activates hypoxia-inducible factor-2α (HIF-2α) (41) and possibly also hypoxia-inducible factor-1α (HIF-1α) under certain conditions (42,43); these represent the principal stimuli for erythropoietin synthesis. Thus, the erythropoiesis that is seen with SGLT2 inhibitors may represent a biomarker for enhanced SIRT1 signaling and its organ-protective effects (Fig. 1). Such a relationship may explain why, in statistical mediation analyses, erythropoiesis has been the most powerful predictor of the action of SGLT2 inhibitors to reduce heart failure events in large-scale trials (44,45).

Third, metformin also stimulates autophagy, primarily by activating AMPK and SIRT1 and suppressing Akt/mTOR (46). Metformin exerts both cardioprotective and renoprotective effects in experimental models, and it favorably influences the evolution of heart failure and nephropathy in cohort studies. The overlap in the mechanism of action between metformin and SGLT2 inhibitors (with respect to AMPK/SIRT1 activation and autophagy) may explain why the magnitude of the benefit of SGLT2 inhibitors in large-scale trials may be attenuated in patients receiving metformin (47). However, metformin suppresses HIF-1α (48), thus distinguishing its action from that of SGLT2 inhibitors; this effect may explain why metformin modestly decreases hematocrit, whereas SGLT2 inhibitors induce erythropoiesis. However, since both HIF-1α and HIF-2α appear to induce autophagy (49,50) in a manner than is independent of AMPK (39), it is possible that enhanced HIF-1α/HIF-2α signaling by SGLT2 inhibitors may amplify the autophagic flux that is already augmented by AMPK/SIRT1, thereby contributing importantly to the striking cardiorenal benefits of these drugs, which are not seen with other glucose-lowering agents.

The conceptual framework described in this Commentary provides a powerful molecular basis for the model described by Avogaro et al. (13) in the current issue. Their proposal for a “dormancy state” is analogous to the fasting transcriptional paradigm that is delineated in this Commentary. However, regardless of how their actions are envisioned, it is now critical for physicians to reconceptualize SGLT2 inhibitors as organ-protective agents rather than glucose-lowering drugs. The antihypoglycemic action of these drugs represents a tiny fraction of their broad portfolio of effects, which (when fully exercised) cause an adaptive reprogramming of stressed cells in a manner that promotes homeostasis and survival.

Duality of Interest. M.P. has recently consulted for AbbVie, Actavis, Akcea, Amgen, AstraZeneca, Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Johnson & Johnson, Novo Nordisk, Pfizer, Relypsa, Sanofi, Synthetic Biologics, and Theravance. No other potential conflicts of interest relevant to this article were reported.

References

15. Meijles DN, Zoumpoulidou G, Markou T, et al. The cardiomyocyte “redox rheostat”: Redox signalling via the AMPK-mTOR axis and regulation of
gene and protein expression balancing survival and death. J Mol Cell Cardiol 2019;129:118—129
40. Schönberger MJ, Krek W, Kovacs WJ. EPAS1/HIF-2α is a driver of mammalian pexophagy. Autophagy 2015;11:967—969